MALVERN, PA — Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, Inc. (NASDAQ: OCGN), is set to deliver a keynote speech at the upcoming Pharma Market Research Conference (PMRC) taking place from February 7-8, 2024, in Newark, NJ. The keynote address, titled “Future Innovations in Healthcare: From Dreaming to Community Health,” promises to offer valuable insights into the evolving landscape of healthcare, particularly gene therapy.
Musunuri’s keynote will highlight the potential of gene therapy to cure debilitating conditions. “Biotechnology has become more nuanced and personalized since its inception. Today, gene therapy holds tremendous promise,” said Dr. Musunuri. He also expressed his eagerness to discuss Ocugen’s first-in-class, gene-agnostic approach to treating blindness diseases, an innovative strategy that could redefine the future of ocular therapeutics.
The PMRC is a renowned gathering of market research executives from the pharma, biotech, medical devices, and diagnostics sectors. It serves as a platform for industry leaders to share insights, discuss trends, and explore the future of their respective fields. Dr. Musunuri’s keynote is eagerly anticipated by attendees, given his position at the helm of one of the leading firms in gene therapy.
The details of Dr. Musunuri’s keynote are as follows:
Event: 15th Annual PMRC
Date: Wednesday, February 7, 2024
Location: Newark Liberty International Airport Marriott
Time: 9-9:30 a.m. ET
With the healthcare industry undergoing rapid changes fueled by advances in biotechnology, the PMRC offers a timely platform for discussions on the future of healthcare. The conference, coupled with Dr. Musunuri’s keynote, promises to shed light on the exciting innovations that lie ahead in the realm of gene therapy and beyond.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.